^
Association details:
| Biomarker: | KIT K642E |
|---|---|
| Cancer: | Melanoma |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II trial of dasatinib in advanced melanoma
Excerpt:
Only one responder, a patient with a primary subungual melanoma, had a K642E substitution mutation in exon 13 of c-kit.
DOI:
10.1002/cncr.25766
